May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Methylglyoxal–modification enhances antiapoptotic properties of alpha–crystallin
Author Affiliations & Notes
  • R.H. Nagaraj
    Ophthalmology, Case Western Res Univ, Cleveland, OH
  • B. Liu
    Ophthalmology, Case Western Res Univ, Cleveland, OH
  • T. Oya–Ito
    Ophthalmology, Case Western Res Univ, Cleveland, OH
  • D.G. Smith
    Ophthalmology, Case Western Res Univ, Cleveland, OH
  • H.A. Pilch
    Ophthalmology, Case Western Res Univ, Cleveland, OH
  • Footnotes
    Commercial Relationships  R.H. Nagaraj, None; B. Liu, None; T. Oya–Ito, None; D.G. Smith, None; H.A. Pilch, None.
  • Footnotes
    Support  R01–EY09912, P30–EY11373, RPB and Ohio Lions Eye Research Foundation
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3967. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R.H. Nagaraj, B. Liu, T. Oya–Ito, D.G. Smith, H.A. Pilch; Methylglyoxal–modification enhances antiapoptotic properties of alpha–crystallin . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3967.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: We have recently demonstrated that methylglyoxal (MGO), an α–dicarbonyl compound present in the lens can chemically modify α–crystallin and enhance its chaperone function (Nagaraj et al., Biochemistry, 42: 10746–10755, 2003). In this study, we have investigated effect of MGO modification on the antiapoptotic properties of α–crystallin. Methods: Bovine lens α–crystallin was incubated with or without 25 mM MGO for one week at 37 0C and pH 7.4 and conjugated with Alexa–350 fluorophore. Alexa–350 conjugated or unconjugated α–crystallin (50 μg) was encapsulated in BioPORTER liposome and incubated with human lens epithelial cells (HLE B–3) for 4 hrs. The cells were then incubated with 1µM staurosporine (STS) for 3 hrs. Apoptotic cells (Annexin V positive) were quantified by flow cytometry. Effect of transfer of native or MGO–modified α–crystallin on reactive oxygen species (ROS) and glutathione (GSH) content was determined. Cytochrome c content was estimated by Western blotting. Effect on caspase–8 mediated activation of capase–3 was also investigated. Results: BioPORTER–mediated transfer of α–crystallin (Alexa–350 conjugated) into HLE B–3 cells was evident by the results of fluorescence microscopy, Western blotting with anti–α–crystallin antibody or anti–argpyrimidine antibody, and ELISA. We achieved approximately 7–8% of crystallin transfer into cells by this method. STS treatment resulted in 24 ± 0.6% apoptotic cells, but after transfer of α–crystallin (not conjugated with Alexa–350) apoptotic cells were considerably reduced (14.9 ± 0.6%). Transfer of MGO–modified α–crystallin further decreased apoptotic cells (6.9 ± 0.8%). GSH content dramatically decreased in cells incubated with STS alone, transfer of native and MGO–modified α–crystallin inhibited GSH loss by 17 and 20%, respectively. Transfer of native or MGO–modified α–crystallin had no significant effect on cytochrome c content. ROS content was significantly lower in cells transferred with MGO–modified α–crystallin when compared to cells that were treated with STS alone. Caspase–8 mediated activation of caspase–3 was inhibited by α–crystallin, but the effect was more pronounced with MGO–modified α–crystallin. Conclusions: Our data suggest that α–crystallin becomes a better antiapoptotic protein after modification by MGO, which may be due to multiple mechanisms, and may involve enhancement of chaperone function, reduction in oxidative stress and prevention of caspase–8–mediated caspase–3 activation.

Keywords: crystallins • protein modifications–post translational • apoptosis/cell death 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×